CSL

The biotech company, one of the largest on the ASX, saw its share price drop despite strong profit growth. Here are three reasons why.

The circa $10 billion Brisbane fundie says market risks are leaning towards the downside as it looks for value the rest of the market has missed.

TMS likes to buy and hold. Up to 70% of its portfolio is made up of picks it made when it was established two decades ago - including CSL, Soul Patts and Brickworks.